# Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma

> **NCT06642506** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 20 (actual)

## Conditions studied

- Esophagus Adenocarcinoma
- Esophagus Cancer
- Metabolome
- Mass Spectrometry
- Precision Medicine
- Oncology Patients Receiving Chemotherapy
- Metabolomics
- Chemoresistance

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06642506
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-06
- **Primary completion:** 2025-06
- **Final completion:** 2025-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642506, "Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06642506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*